Kourosh Dastgheib, MD
Ophthalmology · Garden Grove, CANPI 1578523593
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (58.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Rxsight Inc at 51.1% of the total. Reporting peaked in 2023 at $7,291 and has fallen 92.5% since, to $545 in 2025. Among ophthalmology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 243 payments — averaging $56.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rxsight Inc$7K
- Bausch & Lomb Americas Inc.$2K
- Alcon$1K
- AbbVie$878
- Aerie Pharmaceuticals, Inc.$714
- Sun Pharmaceutical Industries Inc.$428
- plus $1K from 13 others
What the payments were for
- Consulting fees$7,99558%
- Travel & lodging$2582%
- Food & beverage$5,23038%
- Education$1931%
- Gifts$921%
- Entertainment$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Rxsight Inc | 12 | $7,040 |
| Bausch & Lomb Americas Inc. | 28 | $2,420 |
| Alcon | 42 | $1,042 |
| AbbVie(2 entities) | 35 | $878 |
| Aerie Pharmaceuticals, Inc. | 43 | $714 |
| Sun Pharmaceutical Industries Inc. | 18 | $428 |
| Novartis | 21 | $355 |
| Oyster Point Pharma, Inc. | 7 | $194 |
| Kala Pharmaceuticals, Inc. | 9 | $178 |
| Amgen(2 entities) | 5 | $146 |
| Shire North American Group Inc | 11 | $122 |
| Dompe US, Inc. | 3 | $92 |
| Rayner Intraocular Lenses Limited | 2 | $46 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $36 |
| Genentech USA, Inc. | 1 | $35 |
| Biofrontera Inc. | 1 | $19 |
| Optos, Inc. | 1 | $17 |
| Lumibird Medical Inc. | 1 | $15 |
| NEW World Medical,inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RXSIGHT CONTACT LENS$6,595
- RXSIGHT INJECTOR CARTRIDGE$6,595
- RXSIGHT INJECTOR HANDPIECE$6,595
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$6,595
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$6,595
- enVista Aspire IOL$522
- TENEO$372
- STELLARIS ELITE$372
- enVista MX60 IOL$300
- Clareon$135
- DURYSTA$113
How this compares
$13,786 in reported general payments places this provider in the 90th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 29 | $718 |
| Latanoprost | 20 | $283 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Garden Grove
- Daniel SchwartzSan Francisco$8M
- Michael BerlinWest Hollywood$5.7M
- Gilbert KlimanMenlo Park$1.5M
- Kuldev SinghStanford$1.5M
- Raymond DouglasBeverly Hills$1.3M
- John AffeldtLoma Linda$1.1M
- Srinivas SaddaPasadena$1M
- Sheri RowenNewport Beach$1M
- Savak TeymoorianLaguna Hills$955K
- Andrew MoshfeghiLos Angeles$895K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.